Connolly MP, Hoorens S, Chambers G, on behalf of ESHRE Reproduction and Society Task Force. The costs and consequences of assisted reproductive technology: an economic perspective. Human Reproduction Update 2010; online advanced access.
See related Newsweek article (Link)
The Economics of Assisted Reproduction: Costs and consequences of fertility treatments. Mark Connolly thesis download from University of Groningen library.
(http://dissertations.ub.rug.nl/faculties/science/2010/m.p.connolly/).
Connolly MP, Postma MJ. Healthcare as an investment: Implications for an era of ageing populations. J of Medical Marketing 2010; 10:5 -14. (Manuscript available for free download on right).
Hutchings A. Rewarding innovation? An assessment of the factors that affect price and reimbursement status in Europe. J of Medical Marketing 2010; 10:83 -90. (Manuscript available for free download on right).
Connolly MP, Constenla D. Assessing economic benefits for government and society attributed to malaria investment strategies: An exploratory analysis based on malaria vaccination. MIM Pan-African Malaria Conference, Nairobi, November 2009. (Poster available for download by clicking button to right).
Connolly MP, Postma M, Silber S. What's on the mind of IVF consumers? Reproductive BioMedicine Online 2009; 10.1016/j.rbmo.2009.09.032.
Connolly MP. The potential economic benefit of maintaining a healthy workforce should be considered when valuing health technologies. Pharmaceutical Marketing – Feature Article; September 2009.
Connolly MP, et al. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009 (in press).
Connolly, Ledger W, Griesinger G, Postma M. The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: A price-elasticity of demand assessment. Human Reproduction 2009 (accepted for publication).
Connolly M, Bhatt A. Implementation of National Dyspepsia Guidelines to Reduce Prescribing and Return Patients to Self Care: Results from An Educational Intervention and Prospective Clinical Audit in England. Gastroenterology 2009;136(5):A-72.
Wex J, Connolly M, Rath W. Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. BMC Pregnancy and Childbirth 2009, 9:23.
Connolly M, Bhatt A. Implementation of national dyspepsia guidelines to reduce prescribing and return patients to self care: results from an educational intervention and prospective clinical audit in England. Pharmacoepidemiology and drug safety 2009;18: 1–11.
Connolly M, et al. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Human Reproduction 2009; 24(3):626-632.
Connolly M, et al. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis. J. of Crohn's and Colitis (in press).
Svensson A, Connolly M, Gallo F, Hägglund L. Long Term Fiscal Implications of subsidizing In-vitro Fertilization in Sweden: A lifetime tax perspective. Scandinavian Journal of Public Health 2008;36:832-840.
Connolly M, Bhatt A. A comparison of treatment failure rates based on starting alginate therapy observed in a large representative longitudinal UK database. Value in Health 2008;11(6): A530.
Connolly M, Nielsen SK, Currie CJ, Poole C, Travis SPL. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. Journal of Crohn's and Colitis (Accepted Oct 2008).
Connolly M. Pricing and reimbursement challenges for new pharmaceuticals and medical devices. www.lifescience-online.com (Oct 2008).
Connolly MP, Ledger W. Price-elasticity of demand for infertility services in Germany. Value in Health 2008:11(6):
Bhatt A, Connolly M, Travis SPL. Self-diagnosis and health seeking behaviour of women for minor bowel ailments in a large representative United Kingdom (UK) sample population. GUT 2008;57 (Suppl I):A271.
Connolly M, et al. Once daily mesalazine for maintaining remission is cost-saving compared to twice daily mesalazine: An economic evaluation based on the PODIUM randomised controlled trial. GUT 2008;57 (Suppl I):A261.
Connolly M, et al. Long-term economic benefits attributed to IVF conceived children: A lifetime tax calculation. American Journal of Managed Care 2008; 14(9):598-604. (www.ajmc.com)
Connolly M, De Vrieze K, Ombelet W, Schneider D, Currie CJ. A cost per live birth comparison based on a systematic review of hMG and rFSH randomised trials. Reproductive BioMedicine Online 2008;17(6):
Wex J, Connolly M, Schneider D, Rath W, Nielsen SK. Atosiban is cost saving when compared to beta-mimetics in the treatment of preterm labour in Germany. European Congress of Perinatal Medicine September 2008.
Connolly M, Bhatt A, Wechowski J, Colli I. An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastro-enterologica Belgica 2008; 71:230-236.
Moul JW, Wiederkehr D, Connolly M, Sendersky V, Onel E. The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer. J Clin Oncol 26: 2008 (Suppl; 16002).
Moul JW, Wiederkehr D, Sendersky V, Connolly M, Stern L, Onel E. The influence of Medicare reform on the utilization of anti-androgens in a cohort of patients with prostate cancer in the United States. American Society of Clinical Oncology 2008 (Abstract 204).
Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R. Cost saving treatment strategies in IVF: A combined economic evaluation of two large randomized clinical trials comparing HP-hMG and rFSH alpha. Fertility & Sterility; 2008.
Svensson A, Connolly M. Long Term Fiscal Implications of subsidizing in-vitro Fertilization in Sweden - A study using Net Present Value. Nordic Fertility Society Jan 2008; Oslo, oral presentation.
Connolly MP, Hoorens S, Gallo F, Ledger W. Assessment of long term economic benefits associated with in-vitro fertilization funding decisions: A simplified lifetime tax calculation. Value in Health 2007;10(6):ES7.
Nielsen SK, Connolly MP, Bhatt A, Currie CJ. Evaluation of the cost-effectiveness of concomitant oral and topical mesalazine treatment versus oral treatment alone in mild-to-moderate active ulcerative colitis: A decision-analytic model. Value in Health 2007;10(6):A353.
SK Nielsen, CJ Currie, MP Connolly, A Bhatt. Evaluation of improvement in health-related quality of life using oral mesalazine alone or in combination with mesalazine enema in active ulcerative colitis: Results from a randomised controlled trial. Value in Health 2007; 10(6):PR8.
Connolly MP, Nielsen SK, Bhatt A, Currie CJ, Probert CS, Marteau P. Evaluation of the cost-effectiveness of concomitant oral and topical versus oral mesalazine therapy in mild-to-moderate active ulcerative colitis: A decision-analytic model. GUT 2007;56:(Suppl III) A149.
Connolly MP, S. Hoorens, and W. Ledger Money in babies out: Assessing the long-term economic impact of IVF conceived children. J. Medical Ethics 2008;34:653-4.
J Wechowski, P McEwan, MP Connolly, R Kennedy. HP-hMG (Menopur®) is cost-saving in IVF compared to rFSH (Gonal-F®) in an economic evaluation using two large combined randomised controlled trials. Human Reproduction 2007; 22(7):O-052.
Connolly MP, Currie CJ, Nielsen SK. Cost-saving treatment strategies in cervical ripening/labour induction: A cost comparison of two dinoprostone formulations. J Perinat Med 2007;35:(S139)
J Wechowski, M Connolly, P McEwan, R Kennedy. An economic evaluation of HP-hMG and rFSH based on a large randomised trial. Reproductive BioMedicine Online 2007;15:500-06.
M Connolly. Demography is destiny: the long term societal impact of assisted reproduction. Portuguese Infertility Society Annual Meeting (Porto), May 19th 2007 (Invited speaker).
J. Wechowski, M Connolly, A Tetlow, P McEwan et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr Med Res Opin 2007; 23(7):1481-91.
J. Wechowski, P. McEwan, M. Connolly, R. Kennedy. Costs and effectiveness of highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follitropin alpha (rFSH) in IVF treatment: A United Kingdom discrete event simulation model. 19th World Congress on Infertility and Sterility 2007; Durban (oral presentation).
S. Hoorens, F. Gallo, W. Ledger, M. Connolly. The impact of NHS funding decisions for in vitro fertilisation (IVF) on Treasury department revenues: A simplified lifetime net tax calculation. National Institute for Clinical Excellence (NICE) annual meeting, Dec 2006.
L. McCrink, RP. Allen, S. Wolowacz, B. Sherrill, M. Connolly, J. Kirsch. Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. Sleep Medicine (2006);8(1):73-83.
J. Wechowski, T. Tetlow, Al Woehl, M. Connolly, C.J. Currie, A.K. Burroughs. An economic evaluation of terlipressin versus alternative vasoactive drug treatments for acute oesophageal variceal bleeding in cirrhotic patients: A UK decision-analytic model. 14th United European Gastroenterology Week; 2006: Berlin (256).
Ledger W, Gallo F, Hoorens S, Ziebe S, Connolly M. Present discounted value of children born using IVF compared with naturally conceived children: A simplified UK tax calculation. Hum Rep vol. 21(Suppl 1); 2006 (i74).
Wechowski J, Tetlow T, Woehl A, Currie CJ, Connolly M, Bhatt A, Colle I. Economic evaluation of vasoactive management options for acute oesophageal variceal bleeding in cirrhotic patients: A Belgian comparison. Ceska a Slovenska Gastrologie a Hepatologie 2006;60,S1,119.
Connolly M. Impact of introducing reference-based pricing on prescription drug claims in Australia. 5th European Conference on Health Economics, abstract 63, London, Sept 2004.
Lees M, Isaacson, W, Fulcer G, Yue M, Connolly M, Currie CJ. Cost-effectiveness of intensive insulin therapy using insulin glargine versus NPH insulin in an Australian population. International Diabetes Federation Sept. 2003 (Abstract 2922).
|
